Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - Bluebird Bio reported a quarterly loss of $23.74 per share, significantly worse than the Zacks Consensus Estimate of a loss of $6.60, and compared to a loss of $15.60 per share a year ago, indicating an earnings surprise of -259.70% [1] - The company posted revenues of $38.52 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 52.86%, and showing a substantial increase from year-ago revenues of $7.83 million [2] - Over the last four quarters, Bluebird has surpassed consensus EPS estimates just once, while topping consensus revenue estimates two times [2] Stock Outlook - Bluebird shares have declined approximately 55% since the beginning of the year, contrasting with the S&P 500's decline of -2.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.60 on revenues of $47.2 million, and for the current fiscal year, it is -$15.19 on revenues of $282.8 million [7] - The estimate revisions trend for Bluebird is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Bluebird belongs, is currently in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]